Abbott and Tandem finalize partnership to integrate FreeStyle Libre 2 iCGM data with t:slim X2 Pumps - June 30, 2020

Finalized details from October 2019 agreement relating to “technical development” and “commercial support” activities; initial focus on US and Canadian markets

Table of Contents 

Abbott and Tandem announced yesterday that they have finalized details of a partnership integrating Abbott’s recently cleared FreeStyle Libre 2 CGM with Tandem’s insulin pumps.  As a reminder, this partnership was first announced in October 2019, although we’ve heard little about it since. In February, Tandem confirmed the partnership was still being finalized. Notably, Abbott’s press release continues to emphasize pump-CGM interoperability and that the companies have moved beyond the exploratory phase of the agreement, having finalized details pertinent to the “technical development” of necessary device integrations and related “commercial support” activities. It also specifies that the deal will initially focus on US and Canadian markets, leaving open the possibility of expanding in the future.

Overall, Tandem represents Abbott’s third pump partnership following Bigfoot (July 2017 – MDI is also a major part of this partnership) and Insulet (February 2020) while Abbott remains Tandem’s second CGM partner after Dexcom. Today’s announcement is broad, so we can only continue to speculate on what a potential Tandem t:slim X2 pump-FreeStyle Libre 2 CGM integration would resemble (see below).

It’s been an exciting last few weeks for Tandem, which recently acquired popular CGM companion app SugarMate and received expanded pediatric indication for Control-IQ in children ages 6-13 years. As a reminder, Tandem’s t:slim X2 insulin pump was the first pump to receive FDA clearance as an interoperable insulin in February 2019. Notably, today’s announcement also comes on the heels of Tandem’s potential launch of smartphone control for t:slim X2, which appears to have been delayed from original 1Q20 expectations.

Close Concerns’ Questions

  • Will the FreeStyle Libre 2 iCGM send high/low alarms to a Tandem pump screen, prompting a user to scan with their phone or reader to see the real-time value/trend?

  • Does Abbott envision this partnership as meaningfully different from the one it has with Insulet to integrate Omnipod Horizon?

  • Are there specific patient populations Abbott and Tandem are hoping to reach such as type 2s on insulin or MDI users?

  • How will patients and providers be informed on updates within the partnership?

  • Will there be any collaborative efforts between Abbott and Tandem beyond integration?

  • What are the financial terms of the deal (if any)?

  • Has any work on the integration between Libre 2 and t:slim X2 or other future Tandem product offerings (i.e. t:sport pump) begun yet?



--by Hanna Gutow, Ani Gururaj, and Kelly Close